Filing Flows

Filing Flows › Companies › Usana Health Sciences › Cash flow

Usana Health Sciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$20.2M in Q2 2026 · $15.9M over twelve months

Operating cash flow$23.3M
Capital spending−$3.2M
Free cash flow+$20.2M
Cash conversion cycle145 days

Analysis

In Q2 2026, Usana Health Sciences generated $23.3M of operating cash flow and spent $3.2M on capital projects, leaving free cash flow of $20.2M.

Over the twelve months to Jul 4, 2026, operating cash flow was $27.7M; the largest uses were capital spending ($11.8M), partners ($2.7M), taxes on employees’ shares ($2.4M); besides operations, cash came from asset & business sales ($4.0M); the cash balance rose by $17.4M.

Operating cash flow was $23.3M against net income of −$28.0M. The largest differences: impairments +$29.1M, depreciation & amortization +$7.7M, receivables +$6.3M.

Its cash conversion cycle was 145 days (receivables 3 + inventory 172 − payables 30).

Free cash flow

Usana Health Sciences: free cash flow by quarterUsana Health Sciences: free cash flow by quarter$27.1MQ3 2024$4.0MQ4 2024$12.7MQ1 2025$7.2MQ2 2025−$5.2MQ3 2025−$6.2MQ4 2025$7.1MQ1 2026$20.2MQ2 2026
Operating cash flow less capital spending.
Usana Health Sciences: operating cash flow against capital spendingUsana Health Sciences: operating cash flow against capital spendingOperating cash flowCapital spending$29.5M$2.4MQ3 2024$5.8M$1.8MQ4 2024$15.5M$2.8MQ1 2025$12.2M$5.0MQ2 2025−$2.0M$3.2MQ3 2025−$3.4M$2.8MQ4 2025$9.8M$2.6MQ1 2026$23.3M$3.2MQ2 2026
Latest (Q2 2026): Operating cash flow $23.3M, Capital spending $3.2M.

Capital allocation, year by year

Usana Health Sciences: where the cash came from (up) and went (down), by fiscal yearUsana Health Sciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingAsset salesCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $121MFY2021: Asset sales $15KFY2021: Capital spending −$12.8MFY2021: Buybacks −$178M$121MFY2021FY2022: Operating cash flow $104MFY2022: Asset sales $7KFY2022: Capital spending −$10.4MFY2022: Acquisitions −$6.5MFY2022: Buybacks −$25.4M$104MFY2022FY2023: Operating cash flow $70.6MFY2023: Net borrowing $792KFY2023: Asset sales $15KFY2023: Capital spending −$14.5MFY2023: Buybacks −$11.6M$71.4MFY2023FY2024: Operating cash flow $61.0MFY2024: Net borrowing $22.2MFY2024: Asset sales $64KFY2024: Capital spending −$10.1MFY2024: Acquisitions −$203MFY2024: Buybacks −$9.4M$83.3MFY2024FY2025: Operating cash flow $22.3MFY2025: Net borrowing −$9.0MFY2025: Asset sales $3.9MFY2025: Capital spending −$13.8MFY2025: Buybacks −$27.5M$26.3MFY2025
Over these 5 years operating cash flow totalled $379M; the largest uses were buybacks ($252M) and acquisitions ($210M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$169M
Debtnone
Net cash$169M

Usana Health Sciences funds itself: free cash flow was $15.9M over the last twelve months, with $169M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Usana Health Sciences: sources (+) and uses (−) of cash, Q2 2026Usana Health Sciences: sources (+) and uses (−) of cash, Q2 2026Operating cash flow$23.3MNet borrowing (+) / repaid (−)−$14.0MCash drawn (+) / kept (−)−$5.9MCapital spending−$3.2MOther investing−$917KExchange rates$615KTaxes on employees’ shares−$26KAsset & business sales$15K
Usana Health Sciences: sources (+) and uses (−) of cash, TTM to Q2 2026Usana Health Sciences: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow$27.7MCash drawn (+) / kept (−)−$17.4MCapital spending−$11.8MAsset & business sales$4.0MExchange rates$3.6MPartners−$2.7MTaxes on employees’ shares−$2.4MOther investing−$917K

From profit to cash

Usana Health Sciences: net income to operating cash flow, Q2 2026Usana Health Sciences: net income to operating cash flow, Q2 2026Net income−$28.0MDepreciation & amortization$7.7MStock-based pay$3.4MDeferred taxes−$5.3MImpairments$29.1MGains on disposals$13KReceivables$6.3MInventory$2.8MPayables−$401KPrepaid and other assets$2.4MOther liabilities$2.0MOperating cash flow$23.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 2026317230145
Q1 2026315226129

Every quarter

QuarterOperating cash flowCapital spendingBuybacksNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026$23.3M−$3.2M—−$14.0M−$5.9M$20.2M
Q1 2026$9.8M−$2.6M——−$4.4M$7.1M
Q4 2025−$3.4M−$2.8M—$14.0M−$13.1M−$6.2M
Q3 2025−$2.0M−$3.2M——$6.0M−$5.2M
Q2 2025$12.2M−$5.0M−$15.2M−$23.0M$28.2M$7.2M
Q1 2025$15.5M−$2.8M−$12.3M—$2.1M$12.7M
Q4 2024$5.8M−$1.8M—$23.0M$183M$4.0M
Q3 2024$29.5M−$2.4M—$1K−$32.6M$27.1M

Usana Health Sciences: income statement and cash flow

Usana Health Sciences, Q2 2026: revenue $223M (-5% year over year), operating margin -9.0%. The chart follows the revenue to costs, profit and cash.

Usana Health Sciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.